LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025
LENZ Therapeutics (Nasdaq: LENZ), a pre-commercial stage biopharmaceutical company, has scheduled its first quarter 2025 financial results and corporate highlights webcast for May 7th, 2025, at 4:30 p.m. EDT.
The company specializes in developing an innovative aceclidine-based eye drop designed to enhance near vision for individuals with presbyopia, positioning it as the first and only treatment of its kind.
Interested participants can join via:
- Phone: (800) 715-9871 (Domestic)
- Phone: (646) 307-1963 (International)
- Access Code: 8251197
The webcast will be accessible through the company's website at www.LENZ-tx.com in the Investors & Media section, with a replay available for 30 days following the event.
LENZ Therapeutics (Nasdaq: LENZ), una società biofarmaceutica in fase pre-commerciale, ha programmato la trasmissione in webcast dei risultati finanziari e degli aggiornamenti aziendali del primo trimestre 2025 per il 7 maggio 2025 alle 16:30 EDT.
L'azienda si dedica allo sviluppo di un innovativo collirio a base di aceclidina progettato per migliorare la visione da vicino nelle persone con presbiopia, rendendolo il primo e unico trattamento di questo tipo.
Gli interessati possono partecipare tramite:
- Telefono: (800) 715-9871 (nazionale)
- Telefono: (646) 307-1963 (internazionale)
- Codice di accesso: 8251197
Il webcast sarà disponibile sul sito web dell'azienda www.LENZ-tx.com nella sezione Investitori e Media, con una replica accessibile per 30 giorni dopo l'evento.
LENZ Therapeutics (Nasdaq: LENZ), una compañía biofarmacéutica en etapa precomercial, ha programado su webcast de resultados financieros y aspectos corporativos del primer trimestre de 2025 para el 7 de mayo de 2025 a las 4:30 p.m. EDT.
La empresa se especializa en desarrollar un innovador colirio a base de aceclidina diseñado para mejorar la visión cercana en personas con presbicia, posicionándose como el primer y único tratamiento de este tipo.
Los interesados pueden unirse a través de:
- Teléfono: (800) 715-9871 (doméstico)
- Teléfono: (646) 307-1963 (internacional)
- Código de acceso: 8251197
El webcast estará disponible en el sitio web de la compañía www.LENZ-tx.com en la sección de Inversores y Medios, con una repetición accesible durante 30 días después del evento.
LENZ Therapeutics (나스닥: LENZ)는 상업화 전 단계의 바이오제약 회사로, 2025년 1분기 재무 결과 및 기업 주요 소식을 2025년 5월 7일 오후 4시 30분 EDT에 웹캐스트로 진행할 예정입니다.
이 회사는 노안 환자의 근거리 시력을 개선하기 위해 고안된 혁신적인 아세클리딘 기반 안약을 개발 중이며, 이 분야에서 최초이자 유일한 치료법으로 자리매김하고 있습니다.
참여를 원하시는 분들은 다음 방법으로 접속할 수 있습니다:
- 전화: (800) 715-9871 (국내)
- 전화: (646) 307-1963 (국제)
- 접속 코드: 8251197
웹캐스트는 회사 웹사이트 www.LENZ-tx.com의 투자자 및 미디어 섹션에서 시청 가능하며, 행사 후 30일 동안 다시보기 서비스를 제공합니다.
LENZ Therapeutics (Nasdaq : LENZ), une société biopharmaceutique en phase pré-commerciale, a programmé sa diffusion en webcast des résultats financiers et faits saillants du premier trimestre 2025 pour le 7 mai 2025 à 16h30 EDT.
La société se spécialise dans le développement d'une goutte ophtalmique à base d'aceclidinium innovante, conçue pour améliorer la vision de près chez les personnes atteintes de presbytie, faisant d'elle le premier et unique traitement de ce type.
Les participants intéressés peuvent se joindre via :
- Téléphone : (800) 715-9871 (domestique)
- Téléphone : (646) 307-1963 (international)
- Code d'accès : 8251197
Le webcast sera accessible sur le site web de la société www.LENZ-tx.com dans la section Investisseurs & Médias, avec une rediffusion disponible pendant 30 jours après l'événement.
LENZ Therapeutics (Nasdaq: LENZ), ein biopharmazeutisches Unternehmen in der vorkommerziellen Phase, hat seine Webkonferenz zu den Finanzergebnissen und Unternehmens-Highlights des ersten Quartals 2025 für den 7. Mai 2025 um 16:30 Uhr EDT angesetzt.
Das Unternehmen spezialisiert sich auf die Entwicklung eines innovativen Augentropfens auf Aceclidin-Basis, der die Nahsicht bei Personen mit Presbyopie verbessert und somit die erste und einzige Behandlung dieser Art darstellt.
Interessierte können über folgende Nummern teilnehmen:
- Telefon: (800) 715-9871 (national)
- Telefon: (646) 307-1963 (international)
- Zugangscode: 8251197
Der Webcast ist auf der Unternehmenswebsite www.LENZ-tx.com im Bereich Investoren & Medien verfügbar, mit einer Wiederholung, die 30 Tage nach der Veranstaltung abrufbar ist.
- First and only aceclidine-based eye drop for presbyopia, indicating potential market exclusivity
- Pre-commercial stage indicates progress towards market readiness
- Pre-revenue status with no current commercial products
- Likely ongoing R&D expenses without revenue generation
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, May 7th, 2025, at 4:30 p.m. EDT to report its first quarter 2025 financial results and recent corporate highlights.
To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 8251197. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.
About LENZ Therapeutics
LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ’s product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.
Contacts:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
FAQ
When will LENZ Therapeutics (LENZ) report Q1 2025 earnings?
How can investors join LENZ Therapeutics Q1 2025 earnings call?
What is LENZ Therapeutics main product focus?
How long will LENZ Q1 2025 earnings webcast be available?
What stage is LENZ Therapeutics in its development?
